(PDF) PDB21 Chart Audit and Budget Impact Analysis of

PDB21 Chart Audit and Budget Impact Analysis of Pasireotide Versus Second-Line Therapies in the Treatment of Cushing's Disease in Germany

Value in Health - United Kingdom

doi 10.1016/j.jval.2012.08.1664

Full Text

Abstract

Available in full text

Categories

Occupational Health

Date

November 1, 2012

Authors

Publisher

Elsevier BV

Related search

Drugs in the Medical Treatment of Cushing's Syndrome – An Update on Mifepristone and Pasireotide

Expert Opinion on Emerging Drugs

English

Budget Impact Analysis or Pharmacological Therapy of Chronic Myeloid Leukemia (Cml) With Nilotinib as the Second-Line Treatment in Russian Federation

Value in Health

Occupational Health

English

Pcn90 - Cost-Effectiveness and Budget Impact Analysis of Nilotinib for the Second Line Tratment of Chronic Mieloid Leukemia in the Russian Federation

Value in Health

Occupational Health

English

Adrenal Autografts in Treatment of Cushing's Disease

English

‘De-Escalation’ Using Micafungin for the Treatment of Systemic Candida Infection: Budget Impact in France and Germany

Value in Health

Occupational Health

English

Egfr Test-Guided Erlotinib Versus Chemotherapy for First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Budget Impact Analysis

Value in Health

Occupational Health

English

Potential of Omega-3 Fatty Acid in Parenteral Nutrition in Germany: A Budget Impact Analysis

Value in Health

Occupational Health

English

Budget Impact Analysis of Biosimilar Infliximab for the Treatment of Crohn's Disease in Six Central Eastern European Countries

Value in Health

Occupational Health

English

Pms18 - Budget Impact Analysis of Knee Osteoarthritis Viscosupplementation Treatment in Brazil

Value in Health

Occupational Health

English